Myeloperoxidase as therapeutic target in HFpEF
نویسندگان
چکیده
Abstract Background Inflammation and oxidative stress are thought to play an important role in the pathophysiology of HFpEF through development endothelial dysfunction. Myeloperoxidase (MPO), a leukocyte-derived enzyme, functions as link between inflammation is interesting therapeutic target. Purpose To compare MPO levels old controls define clinical characteristics associated with high MPO. Methods Patients (N=55) >60 years (N=18) were prospectively included. All subjects underwent complete echocardiography standard biology. dosed by ELISA assay. Endothelial function was assessed peripheral arterial tonometry reactive hyperemia index (RHI). Characteristics compared using independent samples t-test or chi square test. Results (80±8.5 years, 65% female) had higher myeloperoxidase (74±6.2 72% (34.7 ng/mL [22.7; 43.9] versus 22.5 [18.1; 31.9], p=0.026) (Figure 1). patients above median more often men diabetic NTproBNP CRP. However, not measured RHI (Table Conclusion(s) have than control subjects, reflecting leukocyte activation stress. disease severity. inhibitors could be useful for treatment patients, especially subgroup diabetes. Funding Acknowledgement Type funding sources: Private grant(s) and/or Sponsorship. Main source(s): Fondation Damman
منابع مشابه
The Resurrection of Myeloperoxidase as a Therapeutic Target
SEE PAGE 633 T he innate immune response is critical to our survival as human beings. An important component of the innate immune response is the release of myeloperoxidase (MPO) predominantly from neutrophils upon activation. MPO generates numerous reactive oxidant species and has the unique ability to produce reactive chlorinating species which are particularly potent against invading viruses...
متن کاملP 86: CD166 as a Therapeutic Target in Autoimmune Diseases
About 3 decades ago CD6 identified as one of the first antigens expresses on the majority of T cells and a subset of B cells. CD6 regulates cellular adhesion migration across the endothelial and epithelial cells. In recent years researches indicate its role in pathogenesis of autoimmune diseases. Many researches have been done in recent years to block CD6 by CD6 mono clonal antibodies, IOR-T1 a...
متن کاملp 86: cd166 as a therapeutic target in autoimmune diseases
about 3 decades ago cd6 identified as one of the first antigens expresses on the majority of t cells and a subset of b cells. cd6 regulates cellular adhesion migration across the endothelial and epithelial cells. in recent years researches indicate its role in pathogenesis of autoimmune diseases. many researches have been done in recent years to block cd6 by cd6 mono clonal antibodies, ior-t1 a...
متن کاملBioinformatics-Based Prediction of FUT8 as a Therapeutic Target in Estrogen Receptor-Positive Breast Cancer
Abstract Introduction: Estrogen receptor-positive (ER-positive) breast cancer is a subgroup of breast tumors that is more likely to respond to hormone therapy. ER-positive and ER- negative breast cancers tend to show different patterns of metastasis because of different signaling cascade and genes that are activated by estrogen response. Genetic factors can contribute to high rates of metastas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2022
ISSN: ['2634-3916']
DOI: https://doi.org/10.1093/eurheartj/ehac544.762